Gadoxetate use while Breastfeeding
Drugs containing Gadoxetate: Eovist
Gadoxetate Levels and Effects while Breastfeeding
Summary of Use during Lactation
Although early investigators recommended withholding breastfeeding following administration of gadolinium contrast agents, a more recent and much larger study on another agent, gadopentetate, indicated that the amounts of gadolinium excreted into breastmilk are less than 1% of the amount allowed to be given to infants. In addition, because gadolinium contrast agents are poorly absorbed orally, none is likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[1][2][3] However, because there is no published experience with gadoxetate during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant. The manufacturer states that mothers with normal kidney function can resume nursing 10 hours or more after administration with minimal risk to the infant.[3]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
1. American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2012;Version 8:79-80.
2. Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol. 2005;15:1234-40. PMID: 15609057
3. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112:333-40. PMID: 18669732
Gadoxetate Identification
Substance Name
CAS Registry Number
135326-11-3
Drug Class
- Contrast Media
- Diagnostic Agents
Administrative Information
LactMed Record Number
794
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
2012-08-31
Disclaimer
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
See Also...
- Gadoxetate disodium use during Pregnancy
- Gadoxetate Consumer Information
- Breastfeeding Support Group
- Safe Medications during Breastfeeding
- Medicine use while Breastfeeding
- Medicine use during Pregnancy
Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.
